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Conclusions: Multimodal therapy in SCLC is feasible and requires 
further investigation. TEC produced a high response rate of 92.7%. 
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Background: Several pretreatment characteristics in patients with 
small-cell lung cancer (SCLC) have been associated with meaning-
ful differences in survival. In patients with limited-stage disease,good 
PS, female gender, age younger than 70 years, normal LDH,and stage 
I disease are associated with a more favorable prognosis.In patients 
with extensive-stage disease, normal LDH and a single metastatic site 
are favorable prognostic factors. Recently our study revealed that LD 
stage SCLC treated with multidisciplinary therapy including surgery 
had beter survival outcome. We try to explore clinical and pathologic 
factors that affect the prognosis of SCLC treated with postoperative 
chemotherapy in this retrospective study.
Methods: From Jan 1999 to Dec 2004, 111 patients treated with 
postoperative chemotherapy in our single institute were reviewed 
retrospectively. Postoperative chemotherapy including platin-contained 
or non-platin contained standard regime: CE (Carboplatin AUC 5 d1 
Etoposide 100mg/m2 d1-5,q3w), EP (cisplatin 60-80/mg2 divided into 
3 days/Etoposide 100mg/m2 d1-5,q3w), CAO (Cyclophosphamide 
1000mg/m2 d1/Doxorubicin 45 mg/m2 d1/Vincristine 2mg d1, q3w), 
CAP (Cyclophosphamide 1000mg/m
2
 d1/Doxorubicin 45 mg/m2 d1/
cisplatin 60-80/mg2 divided into 3 days, q3w). Postoperative chemo-
therapy range from 1 to 13 cycles, median cycles 6. Prognostic analysis 
included clinical and pathologic factors related.
Results: The overall median survival time (MST) of SCLC treat with 
postoperative chemotherapy is 38 months, the 1-,3-,5 year survival 
rate was 85.6%, 50.6%, 38.7%,respectively. The signiﬁcant prognostic 
factors for survival in these series of patients were early stage, female, 
no lymphnode metastasis, no lymphovascular invasion (P=0.001), 
and more chemotherapy cycles (p=0.032). According to TNM stage 
system, the MST of stage IA and IB were not reached,for stage IIB, 
IIIA and IIIB was 52 months, 24 months and 13 months (P=0.006), 
respectively. MST of male and female were 35 months and not reached 
(P=0.042); lymphnode metastasis and no lymphnode metastasis were 
26 months and not reached (P=0.001), lymphovascular invasion and no 
lymphovascular invasion were 15 and 51 months, and MST of received 
1-3,4-6 and more than 6 chemotherapy cycles were 26,40months and 
not reached.
For 66 pts with stage III, the MST of postoperative chemotherapy and 
postoperative chemoradiotherapy were 20 and 40 months, 5 years 
survival rate were 26.1% and 45.3% (P=0.071). Cox’s multivariate 
analysis identiﬁed sex (P=0.011), lymphovascular invasion (P=0.002), 
TNM stage (P=0.019), combined radiotherapy (P=0.030) and more 
chemotherapy cycles (P=0.009) as independent prognostic variables. 
Conclusion: For SCLC treated with postoperative chemotherapy, TNM 
stage system was an important prognostic factor, sex, lymphovascular 
invasion,combined radiotherapy and chemotherapy cycles also affect 
overall survival time.
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Purpose: To evaluate the combined modality treatment results of 
patients with limited-stage small cell lung cancer (SCLC).
Patients and Methods: Eighty-three patients with limited-stage SCLC 
diagnosed between 1999 and 2005 were included. All patients were 
treated with chemotherapy and thoracic radiotherapy. Median age 
was 57 years (range 37-76), 90.4% (75) were male and 9.6% (8) were 
female. Median Karnosky Performance Status was 90% (range: 70-
100). Surgery was performed for diagnosis in 3 patients. Median four 
cycles of chemotherapy were administered to 81 patients, composed of 
cisplatin/carboplatin-etoposide (CE) (78 patients), cyclophosphamide-
vincristine-adriamycin (CAV) (1 patient) or alternated CE and CAV (2 
patients). Response to chemotherapy was as follows; complete %44.6, 
partial %32.5, stable %15.7 and progression %4.8. Median total dose 
of radiotherapy was 5600 cGy (range: 4500-6600) with 180-200 cGy 
daily fractions given to the primary tumor and mediastinum, exclud-
ing the spinal cord after 4500 cGy. Response to radiotherapy was as 
follows; complete 66.3%, partial 19.3%, stable 13.3% and progres-
sion 1.2%. Prophylactic cranial irradiation (PCI) was performed in 
42 (50.6%) patients with complete response. Overall survival (OS) 
and progression-free survival (PFS) were calculated from the date of 
diagnosis. Kaplan-Meier method was used for obtaining survival rates. 
Log-rank test was used for univariate analyses. 
Results: Local recurrences were detected in 32 patients (37.5%) and 
distant metastases in 50 (60.2%). Median PFS and OS were 12 (range 
1-76) and 20 (range 7-76) months, respectively. Two-year PFS and OS 
rates were 16.2 % and 21.8 %, respectively. During a median follow-up 
of 57 months 20 (24.1%) patients developed brain metastasis; among 
them only 5 had received PCI before. Univariate analysis showed that 
the complete response to chemotherapy and radiotherapy (p=0.008) 
was a favorable prognostic factor for OS, however no signiﬁcant prog-
nostic factor inﬂuencing PFS was detected.
Conclusion: The prognosis of SCLC is poor despite a combined 
treatment approach. Prognostic factors should be cautiously evaluated 
because of small number and heterogeneous distribution of patients in 
subgroups. Prospective studies are necessary for better determination of 
prognostic factors.
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Background: Combined chemoradiotherapy is the standard treatment 
for patients with limited disease small cell lung cancer (LD SCLC). 
Prophylactic cranial irradiation (PCI) is recommended for complete 
